Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial

Journal of Clinical Oncology

Volumn 19, Issue 14, 2001, Pages 3422-3433

  Hortobagyi, G N ^a   Ueno, N T ^a   Xia, W ^a   Zhang, S ^a   Wolf, J K ^a   Putnam, J B ^a   Weiden, P L ^a   Willey, J S ^a   Carey, M ^a   Branham, D L ^a   Payne, J Y ^a   Tucker, S D ^a   Bartholomeusz, C ^a   Kilbourn, R G ^a   De Jager, R L ^a   Sneige, N ^a   Katz, R L ^a   Anklesaria, P ^a   Ibrahim, N K ^a   Murray, J L ^a   Theriault, R L ^a   Valero, V ^a   Gershenson, D M ^a   Bevers, M W ^a   Huang, L ^a   Lopez Berestein, G ^a   Hung, M C ^a   more..

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; E1A PROTEIN; GENE PRODUCT; LIPOSOME; UNCLASSIFIED DRUG;

ADENOVIRUS; ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEX FORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEVER; GENE OVEREXPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNOHISTOCHEMISTRY; INJECTION PAIN; NAUSEA; ONCOGENE NEU; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; VOMITING;

EID: 0035879090     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.14.3422     Document Type: Article

References (32)

1. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
2. Molecular cloning of the neu gene: Absence of gross structural alteration in oncogenic alleles
3. Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells
4. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase
5. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
6. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
7. Adenovirus E1A-dependent trans-activation of transcription
8. Transactivation by the adenovirus E1A gene
9. Repressed expression of the HER-2/c-erbB-2 proto-oncogene by the adenovirus E1a gene products
10. Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products
11. Involvement of co-activator p300 in the transcriptional regulation of the HER-2/neu gene
12. Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene
13. Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products
14. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A
15. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu
16. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer
17. A novel cationic liposome reagent for efficient transfection of mammalian cells
18. Cationic liposome-mediated gene transfer
19. Adenovirus E1A as a tumor-suppressor gene
20. Tumor suppressive properties of the adenovirus 5 E1A oncogene
21. Strong correlation between c-Erbb-2 overexpression and overall survival of patients with oral squamous cell carcinoma
22. Safety studies of the intraperitoneal injection of E1A-liposome complex in mice
23. Issues in the development of gene therapy: Preclinical experiments in E1A gene delivery
24. Safety study and characterization of E1A-liposome complex gene delivery in an ovarian cancer model
25. Role of tumor necrosis factor-alpha in E1A oncogene-induced susceptibility of neoplastic cells to lysis by natural killer cells and activated macrophages
26. Tumor necrosis factor mediated cytolysis requires the adenovirus E1A protein but not the transformed phenotype
27. Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p105-Rb and induction of DNA synthesis
28. E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of IkappaB kinases and nuclear factor kappaB activities
29. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway
30. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A
31. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway
32. Therapeutic resistance of erbB-2-overexpressing cancers and strategies to overcome this resistance